HAYA Therapeutics

🚀 Are you heading to New York next week?   HAYA team will be participating at the “The Double Helix Den: A closed-door symposium enabling unfiltered conversations on genetic medicines”, hosted by Chardan and Sanofi and "Chardan ’s 9th Annual Genetic Medicines Conference”. Don’t miss the opportunity to hear from our team during the panel discussion sessions, where they’ll share their perspectives on:   -       Beyond the liver: addressing extra-hepatic targets and potential for mass indications -       Partnerships, acquisitions, pricing, and commercial readiness -       RNA Medicines -lncRNAs We're looking forward to engage in meaningful conversations, explore new collaboration opportunities, and share HAYA’s mission to advance a new generation of medicines that harnesses the Regulatory Genome to reprogram disease cells back to a healthy state. 🤝 Would you like to learn what makes HAYA’s approach and platform unique or how targeting the regulatory genome can transform how we treat disease? 🧬 Let’s connect! Meet our team: Jordan Shin, Chief Medical Officer Richard J. Law, Chief Business Officer See you in New York!   ➡️ Swipe for more information or visit https://lnkd.in/eCa2TPTF #Chardan #GeneticMedicines #Biotech #LifeSciences #Networking #Innovation #HAYA #HAYATherapeutics #RegulatoryGenome

We are pleased to share that HAYA Therapeutics will be attending the upcoming HCMA Annual Patient Meeting in Morristown on October 18, 2025. Organized by the Hypertrophic Cardiomyopathy Association (HCMA), this event provides an opportunity for patients, clinicians, and experts to share perspectives on the latest advances in understanding and managing hypertrophic cardiomyopathy (HCM). 🫀 HAYA’s Chief Medical Officer, Dr. Jordan Shin, will be present to hear key discussions and gain valuable insights into patient and clinical experiences that shape the broader HCM community. ➡️ Learn more about the meeting here: https://lnkd.in/e_SW9eMz #HCMA #PatientMeeting #HCM #Awareness #HAYATherapeutics

Attending the BioTechX Europe meeting in Basel next week?   Don’t miss the presentation of Rene Dreos, HAYA’s Principal Data Scientist, to learn more how we leverage multi-omics approaches to decode the Regulatory Genome and identify disease causing lncRNAs” taking place on Tuesday, October 7 at the Single Cell Genomics session. 🧬 We are looking forward to engage with industry leaders and peers and discuss the last advances in innovations in genomics and AI-driven drug discovery.🚀 If you are attending, let’s connect! 🤝 Meet our team: Marco Mina, Senior Dir. Computational Biologist & Data Science Rene Dreos, Principal Data Scientist ➡️ For more information: https://lnkd.in/gHvAR2qS See you in Basel! 🇨🇭 #BiotechX #BiotechXEurope #LifeSciences #Innovation #Networking #Basel #HAYA #HAYATherapeutics #SingleCellGenomics #RegulatoryGenome #lncRNA

Today, we celebrate the 🫀 — one of the oldest and vital organs in our body that makes sure we don’t miss a beat in our lives. Despite of the significant medical advances in the last years, cardiovascular diseases remain as of one of the leading causes of mortality worldwide. This World Heart Day reminds us that we all have a role to play in supporting heart health. At HAYA Therapeutics, we’re dedicated to bringing a new generation of programmable therapeutics that goes beyond traditional approaches and addresses the root cause of disease – the disease cell. Our lead program, HTX-001, is a heart-specific antifibrotic therapy that turns fibrosis driving cells back to healthy state, with the goal of keeping our hearts beating healthier, longer. 🧬 💓 We believe that healthier hearts lead to healthier lives not just for patients, but for their families and all their loved ones. Bringing this vision to a reality is what drive us at HAYA, today and every day! Not sure, what you can do today for you heart? ➡️ Visit the American Heart Association to learn more about healthy living - https://lnkd.in/exkCicU #WHD #WorldHeartDay #PreventHeartDisease #HeartHealthInnovation #CardiovascularBreakthroughs #BiotechInnovation #HeartDiseaseAwareness #HeartCare #CardiovascularInnovation #HealthyHeart #FutureOfMedicine #HAYA #CellStateReprogramming #RegulatoryGenome

We are proud to celebrate the opening of our new home at Lilly Gateway Labs in San Diego — a milestone that reflects not only our growth but also the strength of our vision. At HAYA, we are building the future of RNA medicines by harnessing the power of the regulatory genome to reprogram disease-driving cell states. This bold mission is powered by our extraordinary teams across San Diego and Lausanne, whose dedication and expertise bring our science and our vision to life every day. We are excited to be among the first tenants of this inspiring community and grateful to Eli Lilly and Company and Alexandria Real Estate Equities, Inc. for their support in making this possible. Together, we are advancing towards a future where transformative RNA medicines redefine possibilities for patients worldwide.

✈️ We are attending the European Respiratory Society Congress 2025! This will be our first year attending this meeting and we’re looking forward to connecting with peers, physicians, and potential partners. 🤝 Join our team at the poster sessions to learn more about HAYA pulmonary programs focused on advancing the next-generation solution for the treatment of Idiopathic Pulmonary Fibrosis (IPF) by leveraging the Regulatory Genome. 🧬 🫁 🗓️ Tuesday, 30 September 2025 - Poster 5253 - Room PS-6: 08:00-09:30 CEST - Poster 6337 - Room PS-8: 12:30-14:00 CEST Meet our team: James Karras, PhD, VP Translation Alexandra Iouranova, PhD, Senior R&D Program Lead See you in Amsterdam! 🇳🇱 #ERS2025 #HAYA #HAYATherapeutics #RegulatoryGenome #lncRNA #PosterSession #IPF #LungFibrosis #RNATherapeutics #PrecisionMecidines #CellState #Reprogramming #LungDisease

💯 Samir Ounzain, directeur et cofondateur d’HAYA Therapeutics, fait partie des 100 élus du Forum des 100 du "Temps." Découvrez son portrait par Etienne Meyer-Vacherand. Faire la lumière sur le dark genome Né en Algérie, Samir Ounzain, qui a ensuite grandi au Royaume-Uni, est arrivé en Suisse, plus précisément à Lausanne, en 2011. Il intègre l’unité de cardiologie expérimentale de l’Ecole de médecine de l’Université de Lausanne pour poursuivre ses recherches postdoctorales sur l’implication de l’ARN non codant dans les maladies cardiaques. En 2019, il cofonde la start-up HAYA Therapeutics qui se focalise sur cette partie non codante du génome. Ce dark genome, qui représente 98% de l’ADN, est décrit par Samir Ounzain comme la partie «logicielle» du génome. Celle-ci détermine comment les protéines codées par l’autre partie des gènes «doivent s’assembler, où elles doivent aller et ce qu’elles doivent faire». La start-up lausannoise développe donc une plateforme capable d’identifier des ARN impliqués dans certaines maladies pour permettre la mise au point de traitements à base d’ARN de synthèse ciblant les premiers. HAYA Therapeutics travaille sur un premier traitement contre la fibrose cardiaque, encore en phase préclinique. Ce qui ne l’a pas empêché d’attirer l’attention du géant américain Eli Lilly and Company, avec lequel elle a signé un accord qui pourrait lui rapporter jusqu’à 1 milliard de dollars en 2024. Rendez-vous bientôt pour un nouveau portrait. ➡️ Inscriptions au Forum des 100: https://lnkd.in/eWcW5r6Q

✈️ Will you be attending the 15th Global Summit on Regulatory Science next week?   HAYA’s Director of Regulatory Sciences, Fanny Kling will be attending this year meeting. This summit brings together leading experts, innovators, and regulators, offering a unique opportunity to learn and discuss the latest advancements and challenges in Regulatory Science. Looking forward to engaging in insightful conversations! If you are attending, let’s connect! 🤝   ➡️ Learn more: https://lnkd.in/dd5-D5H4 See you in Lausanne! 🇨🇭 #GCRSR #RegulatoryScience #GlobalSummit #Lausanne #Innovation #Collaboration #Healthcare #LifeSciences #HAYA #HAYATherapeutics #RegulatoryGenome #RNATherapeutics

🚀 We are thrilled to welcome Jérôme Andries as Chief Financial Officer at HAYA Therapeutics!   Jérôme brings over three decades of unparalleled international experience in finance leadership in the pharmaceutical and biotech sectors, including senior roles at GSK, ViiV Healthcare and Eli Lilly and Company.   At HAYA, he will drive our financial strategy and strengthen our financial foundations, ensuring HAYA's sustainable growth and value creation, as we scale across geographies and advance our pipeline of cell state reprogramming medicines. 📈 🧬   ➡️ Learn more: https://lnkd.in/exvvW8PY   🎉 Join us in welcoming Jérôme to the HAYA team!   Follow us and stay tuned for more exciting news!   #CFO #Leadership #Finance #Welcome #GrowthStrategy #ValueCreation #RegulatoryGenome #RNA #HAYA #Innovation #CellStateReprogramming #HAYATherapeutics

✈️ Are you heading to New York for the “Hypertrophic Cardiomyopathy - Comprehensive Management of a Complex Disease; A Case-based Symposium”? Don't miss this opportunity to connect with Jordan Shin, HAYA’s CMO and to learn more about our lead program, HTX-001. This novel antifibrotic agent reprograms fibrosis-driving cells back to a healthy state, offering a complementary approach to current background therapies aimed to treat non-obstructive hypertrophic cardiomyopathy. 🧬🫀 ➡️ Visit us at our exhibit table to know more. HAYA is proud to support this event! 💜 Events like this provides invaluable insights, allowing attendees to learn from leading experts about phenotype, diagnosis and management of both obstructive and non-obstructive hypertrophic cardiomyopathy, helping to raise awareness and improve patients care. ➡️ Learn more: https://lnkd.in/eEBcBQfZ See you in New York! #NYULangoneHealth #HCM #Heart #Cardiology #ComplexDisease #PatientCare #Symposium #HAYA #HAYATherapeutics #RNATherapeutics #lncRNAs #RegulatoryGenome #Fibrosis #CellStateReprogramming NYU Langone Health